Maibo Pharmaceutical-B: interim results announcement for the six months ended June 30, 2022
Is Mabpharm Limited (HKG:2181) Popular Amongst Insiders?
If you want to know who really controls Mabpharm Limited (HKG:2181), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies whil
Increasing losses over year doesn't faze investors as stock spikes 15% this past week
Mabpharm Limited (HKG:2181) shareholders should be happy to see the share price up 15% in the last week. But that doesn't change the fact that the returns over the last year have been less than pl
Maibo Pharmaceutical Co., Ltd.-BRV 2021 Annual report
Maibo Pharmaceutical-B: annual results announcement for the year ended December 31, 2021
Maibo Pharmaceutical-B: date of the Board of Directors
Application for clinical trial of Maibo Pharmaceutical-B (02181.HK) CMAB807X in the treatment of tumor Bone Metastasis approved
[Caihua News] Maibo Pharmaceutical-B (02181.HK) announced that China's State Drug Administration "NMPA" has approved the application of CMAB807X for clinical trials in the treatment of tumor bone metastasis. CMAB807X (deschumab) is a kind of human IgG2 monoclonal antibody, which has affinity and specificity to human RANKL (nuclear factor κ-B ligand receptor activator). RANKL is a transmembrane or soluble protein, which is very important for the formation, function and survival of osteoclasts (cells responsible for bone resorption). CMAB807 prevents RANKL from activating it during bone breakage.
Application for clinical trial of desuximab from 02181.HK Pharmaceutical Co., Ltd. Approved
Maibo Pharmaceutical-B (02181.HK) announced that China's State Drug Administration (SDA) has approved an application for a clinical trial of CMAB807X (deschumab) in the treatment of bone metastasis of tumors. CMAB807X is a kind of human IgG2 monoclonal antibody, which is expected to be used to treat bone metastasis of tumor and giant cell tumor of bone and prevent bone related events in patients with solid tumor bone metastasis and multiple myeloma after the application of new drug is approved.
Maibo Pharmaceutical-B  is now trading at HK $0.89, down 10.10%.
Phoenix New Media Hong Kong shares | as of 13:05, Maibo Pharmaceutical-B  was quoted at HK $0.89, down HK $0.10 or 10.10% from yesterday's closing price, with a turnover of HK $5300, with a high price of HK $0.89 today and a lowest price of HK $0.89. according to yesterday's closing price, the 10-day average price is HK $0.96, the 50-day average price is HK $1.02, and the current price-to-earnings ratio is 0.00 times earnings. The 14-day strength index was 50.00.
Maibo Pharmaceutical-B (02181.HK) renews Shanghai property Lease Agreement
02181.HK announced that as the existing lease agreement expires on December 31, 2021, Baimiber and Sheng Heng entered into a 2021 lease agreement on December 10, 2021 to renew the lease term for another 3 years. The property is located at No. 301 Libing Road, Zhangjiang High-tech Park, Shanghai, with a total area of 3218 square meters.